logo-loader

SkinBioTherapeutics expands food supplement study after receiving an "extraordinary" number of applications

Published: 08:27 01 Feb 2021 GMT

SkinBioTherapeutics PLC -
The company's breakthrough is aimed at addressing the over-production of new skin cells often seen in aggressive skin conditions such as psoriasis

SkinBioTherapeutics PLC (LON:SBTX) said its subsidiary AxisBiotix has expanded its food supplement study by 50 participants to 250 following a "high level of demand”.

Chief executive Stuart Ashman said he was “overwhelmed” by the “extraordinary number of applicants” in a very short period of time, the majority of which were psoriasis sufferers.

Enrolment began on January 14 for the self-managed assessment, which will be monitored through a mobile app that involves answering questions evaluating symptom progression.

The company, with the help of partner Winclove Probiotics, has developed a food supplement that is a blend of bacterial strains designed to balance the gut microbiome.

Specifically, it is designed to address the overproduction of new skin cells often seen in aggressive skin conditions such as psoriasis.

"The high demand for places on the study underlines just how prevalent skin conditions such as psoriasis are, and how keen sufferers are to try something new and natural to alleviate their symptoms. If we can, we want to help as many people as possible,” said CEO Ashman in a statement.

HANetf founder and co-CEO discusses shift to active management in ETF market

HANetf founder and co-CEO Hector McNeil tells Proactive's Stephen Gunnion about shifting trends in the exchange-traded fund (ETF) market in the United States, indicating a big move towards active management within ETFs. Despite the European market lagging behind the US by three to five years,...

15 hours, 47 minutes ago